Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Merck Canada Inc.

Other

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Msd Italia S.r.l.

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

John W Butcher

Nigel J Liverton

David A Claremon

John A McCauley

Wayne J Thompson

Alan B Northrup

Christopher F Claiborne

Ryan D Otte

John Michael Ellis

Harold G Selnick

Michael D Altman

Maria Emilia Di Francesco

Michael T Rudd

Andrew M Haidle

Joon Jung

Christian Fischer

Hua Zhou

Philip Jones

Anandan Palani

Mark T Bilodeau

Robert G Aslanian

Christopher J Dinsmore

David James Witter

Xianhai Huang

Jason D Brubaker

Kevin D McCormick

Jongwon Lim

Hongjun Zhang

Ying Huang

Daniel Guay

Steven D Young

Jacques Yves Gauthier

Phieng Siliphaivanh

Michelle R Machacek

Mark E Layton

Yves Ducharme

Joshua Close

Solomon D Kattar

Vincenzo Summa

Philip E Sanderson

Marco Ferrara

David Joseph Guerin

Purakkattle J Biju

Brian M Andresen

James Patrick Jewell

Tony Siu

Cory R Theberge

Kenneth L Arrington

Michael Hale Reutershan

David G Melillo

Matthew Christopher

M Katharine Holloway

Peter M Munson

Charles J McIntyre

Brian T Phillips

Joseph J Romano

Kaleen Konrad Childers

Scott Peterson

Brian E Libby

Kevin T Nguyen

Thomas J Blacklock

Wei Zhou

Binyuan Sun

Steven Harper

Sandra Lee Knowles

Brandon Mitsuo Taoka

Anthony Donofrio

Paul Sohar

Corey E Bienstock

Kerrie Spencer

Christian Beaulieu

Vouy Linh Truong

Brandon D Cash

Kevin F Gilbert

Alexey A Rivkin

Graham Frank Smith

Michelle Martinez

Joel S Robichaud

Thomas M Connolly

Ning Shao

Rachel Nicola MacCoss

Eric Thomas Romeo

Li Dong

June J Kim

Dilrukshi Vitharana

Kenneth S Koblan

Sean P Ahearn

Jean-Francois Fournier

Christine Dieckhaus

Dennis C Dean

Matthew L Maddess

Marco Pompei

Willie Whitter

Jerzy Karczewski

Theresa R Lamanec

John T Hendrix

Matthew J Kostura

Brandon M Taoka

Raksha Archarya

Marcello Di Filippo

A system for the application of mascara. The system has a container and an applicator wand. The applicator wand has a handle that extends along a central axis. A wand shaft extends from the handle and hold a brush head. The brush head includes a brush held in an articulable mount. The articulable mount orients the brush in a position where the central axis of the handle intersects the center line of the brush at a point between the ends of the brush. The brush is biased to a first angle of inclination. The articulable mount provides a hinge joint between the brush and the wand shaft. The hinge joint enables the brush to temporarily rotate about the hinge joint away from its first angle of inclination and into a second angle of inclination to pass into or out of the access opening of the container.

Mascara applicator system with pivoting offset brush head

A system for the application of mascara to both eyes using the dominant hand. The system has a container and an applicator. The applicator is used to transfer mascara from the container to the eyes. The applicator has a handle, a brush head and a rod. The handle progresses along an imaginary midline and supports the brush head in line with, or parallel to, the midline. The rod has at least one offset section. The rod is long enough to enable a person to position the brush head in front of the left eye from the right side of the head, or in front of the right eye from the left side of the head. The offset section of the rod prevents the applicator from blocking the vision from a near eye when applying mascara across the face to a far eye.

Mascara applicator system for applying mascara with the dominant hand

The invention provides certain thiazole-substituted aminoheteroaryl compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein ring R, R, R, R, ring B, and the subscript r are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors

The present invention provides novel pyrazole derivatives of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

Pyrazolyl derivatives as Syk inhibitors

The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase. 

2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors

The instant invention provides compounds of formula I which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

Azaindoles as Janus kinase inhibitors

A class of macrocyclic compounds of formula (I), wherein R, R, R, R, R, A, Z, Y, X, M, W, n and m are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes 5 for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. Formula (I): 

Macrocyclic compounds as antiviral agents

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R, R, R, R, R, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction.

[object Object]

The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. 

HCV NS3 protease inhibitors

Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions. 

4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists

Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.

N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists

Compounds represented by Formula (I): (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain 

N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists

The present invention is directed to the radioligand compound, [S]-radiolabeled (+)-N-[1'-(6-cyano-1,2,3,4-tetrahydro-2(R)-naphthalenyl)-3,4-dihydro-4(R)-hydoxyspiro[2H-1-benzopyran-2,4&#x2032;-piperidin]-6-yl]methanesulfonamide. Also within the scope of this invention is a method for identifying compounds that bind to the Ichannel, and may have antiarrhythmic activity.

Radioligand and binding assay

Substituted pyridones having cytokine inhibitory activity

Growing community of inventors

Telford, PA, United States of America

John W Butcher